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Background: Pre-exposure prophylaxis (PrEP) is a 
highly effective HIV prevention strategy for men-who-
have-sex-with-men (MSM). The high cost of PrEP has 
until recently been a primary barrier to its use. In 2017, 
generic PrEP became available, reducing the costs by 
90%. Aim: Our objective was to assess cost-effec-
tiveness and costs of introducing PrEP in Germany. 
Methods: We calibrated a deterministic mathemati-
cal model to the human immunodeficiency virus (HIV) 
epidemic among MSM in Germany. PrEP was targeted 
to 30% of high-risk MSM. It was assumed that PrEP 
reduces the risk of HIV infection by 85%. Costs were 
calculated from a healthcare payer perspective using 
a 40-year time horizon starting in 2018. Results: PrEP 
can avert 21,000 infections (interquartile range (IQR): 
16,000–27,000) in the short run (after 2 years scale-
up and 10 years full implementation). HIV care is pre-
dicted to cost EUR 36.2 billion (IQR: 32.4–40.4 billion) 
over the coming 40 years. PrEP can increase costs by 
at most EUR 150 million within the first decade after 
introduction. Ten years after introduction, PrEP can 
become cost-saving, accumulating to savings of HIV-
related costs of EUR 5.1 billion (IQR: 3.5–6.9 billion) 
after 40 years. In a sensitivity analysis, PrEP remained 
cost-saving even at a 70% price reduction of antiretro-
viral drug treatment and a lower effectiveness of PrEP.
Conclusion: Introduction of PrEP in Germany is pre-
dicted to result in substantial health benefits because 
of reductions in HIV infections. Short-term financial 
investments in providing PrEP will result in substantial 
cost-savings in the long term.
Introduction
Sex between men is the predominant route of trans-
mission of human immunodeficiency virus (HIV) in 
Europe [1]. In Germany, the number of new HIV diagno-
ses among men who have sex with men (MSM) remains 
high, with almost 2,000 new diagnoses in 2016 [2], 
despite the availability of condoms, high coverage of 
antiretroviral drug treatment for individuals diagnosed 
with HIV and high levels of virological suppression 
in people using treatment. The large number of new 
diagnoses indicates that additional HIV prevention 
approaches are needed. One such prevention method, 
pre-exposure prophylaxis (PrEP) with the antiretroviral 
drugs tenofovir disoproxil fumarate (TDF) and emtricit-
abine, has been shown to prevent new HIV infections 
in MSM at high risk of infection [3-5]. In trials, PrEP 
reduced the risk of HIV infection by 85% irrespective 
of whether it was used daily [4] or on-demand, where 
individuals took a double dose 2–24 h before sexual 
contact and two single doses 24 and 48 h later [5]. 
Community studies have also shown high PrEP effec-
tiveness among individuals vulnerable to HIV infection 
in real-world settings [6].
The high cost of PrEP was until 2017 a primary limita-
tion for its use in HIV prevention [7]. The patent on TDF 
and emtricitabine, however, expired in 2017, resulting 
in a generic price of EUR 50 per 28 days in Germany, 
which was more than 90% lower than the EUR 700 per 
28 days that had to be paid for branded TDF and emtric-
itabine [8]. Despite this strong reduction in costs, PrEP 
is not reimbursed in Germany and eligible individuals 
have to pay for PrEP out of their own pocket. Use of 
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PrEP can, however, be associated with substantial soci-
etal health benefits by averting HIV infections [4,5]. In 
addition, preventing new infections by introducing PrEP 
could result in financial societal benefits as individuals 
living with HIV require life-long treatment which con-
trary to PrEP is fully reimbursed in Germany.
The aim of this study was to assess the cost-effec-
tiveness and budgetary effect of introducing PrEP in 
Germany. For this purpose, we used a mathematical 
transmission model [9]. The model includes the indi-
vidual HIV-preventive benefit of PrEP among MSM at 
high risk of HIV infection, and the population preven-
tive benefit of PrEP that is due to reducing the number 
of secondary infections in populations where PrEP is 
introduced [9].
Methods
Mathematical transmission model
For this study, we adapted an existing mathematical 
transmission model from the Netherlands [9] to the HIV 
epidemic among MSM in Germany. The Dutch and the 
German HIV epidemics are comparable with nearly 70% 
of infected individuals in both countries reporting MSM 
as the mode of transmission [2,10]. The German HIV 
epidemic is well described by the national Robert Koch 
institute, which collects epidemiological information 
Table
Key model parameters and costs, cost-effectiveness analysis of pre-exposure prophylaxis for HIV prevention in Germany
Description Estimate or rangea Reference
Model parameters
Duration of disease stages
Acute stage 10–16 weeks [38]
CD4+ T-cell count 350–500 cells/µL 2.9–3.1 years [39]
CD4+ T-cell count 200–349 cells/µL 3.6–3.9 years [39]
CD4+ T-cell count < 200 cells/µL 13–25 months [39]
Infectivity per partnership transmissibility per year
Acute stage 0.030–0·61 [13]; Model calibration
Chronic stage 0.027–0·21 [13]; Model calibration
AIDS stage 0.008–0·27 [13]; Model calibration
On Treatment 80–96% reduction in transmissibility compared with chronic stage [14-16]
Proportion of people in sexual risk groups
Highest 6–15%
Model calibration, the sum of the four 
groups was equal to 100%
2nd 10–45%
3rd 10–45%
Lowest 4–70%
Number of partners per year in each sexual risk group
Highest > 30–148
Model calibration
2nd > 5–30
3rd > 0.5–5
Lowest 0.02–0.5
Mortality rates per year
Population 0.0155 [40]
Chronic HIV stage 0.114 [40]
AIDS stage 0.648 [40]
On treatment 0.0184 [40]
Primary cost parameters (costs listed are in 2015 euros) from a healthcare payer perspective
Yearly cost of ART and patient monitoringb EUR 17,016 Local data
Yearly cost of PrEPc EUR 824 Local data
AIDS: acquired immunodeficiency syndrome; ART: antiretroviral drug treatment; HIV: human immunodeficiency virus; PrEP: pre-exposure 
prophylaxis.
a All ranges were uniformly distributed.
b Averaged across regimens by percentage of patients on different regimens. Includes costs of ART, clinic visits, biannual viral load and yearly 
CD4+ T-cell count.
c Includes cost of PrEP, patient monitoring, HIV testing every 3 months, testing for sexually transmitted diseases (including hepatitis C, 
syphilis, chlamydia and gonorrhea) every 6 months.
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including key parameters such as the number of new 
diagnoses and the route of transmission [11].
Model assumptions and calibration
The Dutch mathematical model was adapted using 
parameters that represent the German HIV epidemic 
among MSM from 2013 to 2015 (Table and Supplement). 
The model stratifies disease progression into the acute 
stage, three chronic stages (CD4+ T-cell count > 500 cells/
μL, CD4+ T-cell count 350–500 cells/μL, and CD4+ T-cell 
count 200–349 cells/μL) and one acquired immunode-
ficiency syndrome (AIDS) stage (CD4+ T-cell count < 200 
cells/μL). The schematic representation of the model 
and the equations can be found in the Supplement pp 
1–6. Each stage of infection has a different duration 
and infectivity (Table) [12,13]. We assumed that antiret-
roviral drug treatment for HIV reduces the infectivity by 
80–96% [14-16]. In the baseline scenario with no PrEP, 
we assumed that individuals are tested at a rate that 
allows the modelled CD4+  T-cell count distribution at 
diagnosis to match the CD4+  T-cell count distribution 
at diagnosis in 2015 in the Germany among newly 
diagnosed MSM.
We calibrated our model to the historic HIV epidemic 
based on the estimated population size of German 
MSM [17], the number of MSM diagnosed with HIV, the 
percentage diagnosed with a CD4+ T-cell count greater 
than 500 cells per μL, the percentage diagnosed with 
a CD4+ T-cell count less than 200 cells per μL, and the 
estimated number of MSM living with HIV in Germany 
[11] (Supplementary Table S1). The model included four 
different sexual risk groups with different levels of sex-
ual activity based on the annual number of new sexual 
partners. The annual number of new sexual partners 
ranged from > 30 to 148 in the group with highest sex-
ual activity, > 5 to 30 in the group with second highest 
sexual activity, one to five partners per 2 years in the 
third group and finally less than one new partner every 
2 years in the group with lowest level of sexual activ-
ity. Monte Carlo filtering techniques using wide ranges 
of sexual activity in the different groups allowed us 
to identify which sexual risk group combinations 
resulted in the appropriately calibrated HIV epidemic. 
We accepted 862 of 1 million simulations that matched 
the German HIV epidemic among MSM. All results are 
reported as median and interquartile range (IQR) of the 
accepted simulations.
PrEP was targeted at 30% of the two most sexually 
active groups in the model, which are defined as high-
risk, or at a median of 60,000 MSM at high risk of 
infection. PrEP was initiated in 2017 and scaled up over 
Figure 1
Short-term epidemiological impact of PrEP on HIV 
prevention, modelled cost-effectiveness, Germany, 
2018–2030
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HIV: human immunodeficiency virus; MSM: men who have sex with 
men; PrEP: pre-exposure-prophylaxis.
Short-term (2018–2030) epidemiological impact on the German 
HIV epidemic of PrEP targeted at 60,000 MSM at high risk of 
HIV infection and at 85% effectiveness in reducing the risk for 
HIV infection. The lines represent the predicted number of HIV 
infections that will be averted based on 862 simulations that were 
calibrated to the historic German HIV epidemic. The red line is the 
median value, and the interquartile ranges are represented by the 
blue line (first quartile) and the green line (third quartile).
Figure 2
One-way sensitivity analysis of the modelled change 
in costs of HIV care and prevention over 40 years, 
comparing PrEP use with no PrEP, Germany, 2018–2058
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ART: antiretroviral drug treatment; MSM: men who have 
sex with men; HIV: human immunodeficiency virus; PrEP: 
pre-exposure-prophylaxis.
The annual price of PrEP ranged between EUR 821 for generic 
PrEP and EUR 8,123 when using branded tenofovir alafenamide 
fumarate. The annual cost for ART was ranged between the current 
price of EUR 17,000 (which included antiretroviral drugs and direct 
and indirect health care costs) and EUR 3,500 which would be the 
cost if the price of antiretroviral drugs were reduced by 90% and 
the indirect and direct health care costs remained the same at EUR 
2,000 per year. The coverage of PrEP in low-risk individuals (or 
the proportion of individuals in the two groups with lowest sexual 
activity) ranged between 0 and 30%. The coverage in high-risk 
MSM (or the proportion of MSM in the two groups with highest 
sexual activity) ranged between 10% and 65% [7].
The dashed line represents the budget effect of introducing PrEP 
targeted to 30% of individuals at the highest level of sexual 
activity and at an effectiveness of PrEP of 85%.
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2 years. The median duration of PrEP use was assumed 
to be 5 years or until HIV diagnosis. Individuals using 
PrEP were assumed to receive an HIV test every 3 
months. In our model, it was assumed that infected 
individuals start antiretroviral drug treatment immedi-
ately after diagnosis as recommended in the German 
HIV treatment guidelines [18].
Cost-effectiveness and budget effect of PrEP
The cost-effectiveness was calculated from the health-
care payer perspective, assuming that PrEP is reim-
bursed. Each compartment in our deterministic model 
was assigned a cost and quality-adjusted life years 
(QALY). The costs in our analysis were based on micro-
costing of the unit costs of each component of resource 
use [19] by 362 German HIV-infected MSM that were 
included in 17 centres as reported elsewhere [20]. The 
values have been adjusted to reflect 2016 values using 
the harmonised German general consumer price index 
[21]. The cost components that we included were costs 
of the antiretroviral drugs, direct healthcare costs and 
indirect healthcare costs. The costs of antiretroviral 
drugs were based on the on the costs of the weighted 
mean of the antiretroviral drug regimens used in 
Germany [22] (Supplementary Table S3). Direct health-
care costs included outpatient visits to an HIV special-
ist and to other medical specialists, hospitalisation 
and rehabilitation (Supplementary Table S4). Indirect 
healthcare costs included home care, domestic 
help, travel costs and sick leave (included because 
health insurance in Germany pays sick leave exceed-
ing 6 weeks, while the costs of the first 6 weeks 
were not included as these are paid by the employer) 
(Supplementary Table S4). The costs that we included 
for PrEP were the price of antiretroviral drugs used as 
PrEP, the costs of visiting a physician who prescribes 
PrEP and the costs of monitoring side effects of teno-
fovir (e.g. creatinine) and monitoring sexually trans-
mitted infections (including HIV, syphilis, hepatitis C 
and other bacterial sexually transmitted infections) 
(Supplementary Table S2).
We calculated the budget effect and QALY gained 
over a 40-year period, which was the estimated lifes-
pan between the average age at HIV diagnosis and 
the male life expectancy in Germany. Costs and QALY 
were discounted at 3% per year [23]. Cost-effectiveness 
was calculated as the QALY gained divided by the dif-
ference in costs comparing PrEP to no PrEP. The QALY 
weights can be found in Supplementary Table S5. The 
total budget effect was the difference in costs compar-
ing PrEP to no PrEP.
Sensitivity analysis
We performed a univariate sensitivity analysis of the 
cost-effectiveness and budget effect of introducing PrEP 
compared with not using PrEP. Six key input variables 
were considered to assess the sensitivity of our model. 
The yearly cost of antiretroviral drug treatment was 
ranged between the price of EUR 17,000 and EUR 3,500 
(the lower range of EUR 3,500 reflected a, assumed 
reduction of the annual antiretroviral drug costs of EUR 
15,000 by 90% plus EUR 2,000 for direct and indirect 
healthcare costs;  Table  and  Supplementary Table S4). 
We also varied the annual price of PrEP between EUR 
821 for generic PrEP (Table) and EUR 8,123 for tenofovir 
alafenamide fumarate (TAF), a different prodrug of ten-
ofovir. The effectiveness of PrEP was ranged between 
45%, the lowest efficacy of PrEP reported among MSM 
[3], and 95%. In the sensitivity analysis, the coverage 
of PrEP among MSM at high risk for HIV infection was 
varied between 10% and 65% [7]. We also varied the 
coverage of PrEP among MSM at low risk of infection 
from 0% to 30%. Finally, we did a multivariate sensi-
tivity analysis using recursive partitioning to determine 
the most influential independent parameter on the 
budget effect of PrEP (Supplement, pp 8–9).
Results
Impact of PrEP on the HIV epidemic
At 85% effectiveness, PrEP could prevent 21,000 (IQR: 
16,000–27,000) new infections in the short run (after 
2 years scale-up and 10 years full implementation), if 
targeted to 30% of MSM at high risk of HIV infection 
(Figure 1).
Figure 3
Short-term cumulative costs of a PrEP programme, 
modelled cost-effectiveness, Germany, 2018–2058
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HIV: human immunodeficiency virus; MSM: men who have sex with 
men; PrEP: pre-exposure-prophylaxis.
The lines in the graph represent the change in the discounted 
cumulative costs, defined as the difference between a scenario 
in which PrEP is available and PrEP is not available, at different 
effectiveness of tenofovir disoproxil fumarate and emtricitabine 
in reducing the risk for HIV infection. PrEP is assumed to start in 
2018 (year 0 on the horizontal axis). Data are only presented for 
those years after introduction in which the costs of PrEP exceeded 
the costs of infections that will be averted. The break-even 
point is represented by the point where the lines cross the axis 
representing the number of years after introduction of PrEP.
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At 85% effectiveness and 3% yearly QALY discounting, 
the introduction of PrEP was predicted to result in a 
median gain of 200,000 QALY (IQR: 150,000–270,000) 
over 40 years. Ranging the yearly QALY discounting 
rate resulted in a median gain of 290,000 QALY (IQR: 
210,000–380,000) at a yearly rate of 1.5% and 150,000 
QALY (IQR: 110,000–200,000) at a yearly rate of 4.5%.
Budget effect of PrEP
Treatment and monitoring of patients infected with HIV 
was predicted at a discounted cost of EUR 36.2 bil-
lion (IQR: 32.4 billion–40.4 billion) over the coming 40 
years in Germany. At 85% effectiveness, introduction of 
PrEP at a generic price was predicted to be cost-saving 
and to reduce the discounted costs of HIV care by EUR 
5.1 billion (IQR: 3.5 billion–6.9 billion) over a 40-year 
time period. We did not calculate a cost-effectiveness 
ratio as introduction of PrEP would result in substan-
tial health gains (measured as a reduction of infections 
and as a gain of QALY) at a lower cost compared with 
the situation without PrEP.
Figure 2 shows the one-way sensitivity analysis about 
the impact of six key parameters on the budget effect. 
Introduction of PrEP was only predicted to result in 
increased costs if a branded version of TAF was used 
as PrEP. The increased discounted costs of branded 
TAF were EUR 1.66 billion or a cost-effectiveness ratio 
of EUR 8,500 per QALY. Although the budget effect was 
also sensitive to the price of antiretroviral drug treat-
ment, introduction of PrEP was predicted to remain 
cost-saving even at the strongest reduction in the 
costs of antiretroviral drug treatment by 90% (to EUR 
3,500/year). The sensitivity analysis also showed that 
PrEP would save at least EUR 2 billion in discounted 
costs for the most pessimistic ranges of the other key 
parameters including an increased yearly discounting 
rate of 4.5%, a reduced effectiveness of PrEP of 45% 
in preventing new infections, a reduction to 10% of the 
proportion of high-risk MSM that receive PrEP and a 
proportion of 30% of MSM at low risk of infection who 
receive PrEP (Figure 2).
The annual price of PrEP ranged between EUR 821 
for generic PrEP and EUR 8,123 assuming the use of 
branded TAF. The annual cost for antiretroviral drug 
treatment was ranged between EUR 17,000 and EUR 
3,500. We ranged the coverage of PrEP in low-risk 
individuals (or the proportion of individuals in the two 
groups with lowest sexual activity that will use PrEP) 
between 0 and 30%. The coverage in high-risk MSM (or 
the proportion of MSM in the two groups with highest 
sexual activity) was ranged between 10% and 65% [7].
Figure 4
Cumulative costs (annually discounted at 3%) during 
the first 10 years after introduction of PrEP, stratified 
by effectiveness of PrEP and reduction in costs of 
antiretroviral drug treatment, cost-effectiveness model, 
Germany, 2018–2029
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PrEP: pre-exposure prophylaxis.
Costs are shown as million EUR. The undiscounted costs can be 
found in Supplementary Table S6.
Figure 5
Minimum of years to reach break-even point in which 
the cumulative discounted (at an annual rate of 3%) costs 
of averted HIV infections exceed the costs of a PrEP 
programme, cost-effectiveness model, Germany, from 
2018 onwards
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HIV: human immunodeficiency virus; PrEP: pre-exposure 
prophylaxis.
The analysis is stratified by the effectiveness of PrEP in reducing 
the risk of HIV infection and by the future costs of antiretroviral 
drug treatment compared with the current costs. PrEP is assumed 
to be initiated in 2018. The break-even point for the undiscounted 
costs can be found in Supplementary Table S7.
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Although PrEP was predicted to be cost-saving in the 
long term, introduction of PrEP could in the first 10 
years result in increased expenditure of HIV-related 
costs ranging between a discounted EUR 135 million 
and EUR 275 million for an effectiveness of 95% and 
45%, respectively (Figure 3). The break-even point, cal-
culated as the number of years when the cumulative 
savings from averted HIV infections begin to exceed 
the costs of a PrEP programme [24], was reached after 
10 years. In  Figure 3, we also show that the short-
term costs and the break-even point were predicted to 
depend on the effectiveness of PrEP in daily practice. 
At an effectiveness of 45%, the break-even point was 
reached after 45 years. Similarly, at an effectiveness of 
95%, PrEP cost at most EUR 135 million and the break-
even point was reached after 9 years.
Because the one-way sensitivity analysis showed that 
a reduction in the future costs of antiretroviral drugs 
would have a profound impact on the budget effect 
of PrEP, we further explored the short-term economic 
costs and the break-even point in a two-way sensitivity 
analysis in which we ranged the costs of antiretroviral 
drugs and the effectiveness of PrEP (Figures 4 and 5). 
The cumulative costs after 10 years were predicted to 
be higher at a lower effectiveness of PrEP in reducing 
the risk of HIV infection. Higher cumulative costs were 
also found at the strongest reductions in the price of 
antiretroviral drug treatment. The cumulative costs 
were predicted to remain below EUR 300 million after 
10 years, except when PrEP had an effectiveness of 
45% and the price of antiretroviral drugs was reduced 
by 90% (Figure 4). Figure 5 shows that the break-even 
point also strongly depended on the effectiveness of 
PrEP and a possible reduction in the price of antiretro-
viral drug treatment. If PrEP is at least 45% effective, 
introduction of PrEP is predicted to become cost-saving 
within 20 years at a reduction in the price of antiretrovi-
ral drug treatment of at most 50%. At a lower effective-
ness of PrEP and at price reductions exceeding 50%, 
the break-even point occurred later. Reductions in the 
price of antiretroviral drug treatment by more than 50% 
move the break-even point to between 20 and 25 years 
after introduction of PrEP. A strong reduction in the 
price of antiretroviral drug treatment of more than 80% 
at an effectiveness of PrEP of 45% resulted in a break-
even point reached after more than 25 years.
Discussion
Our model predicts that the use of PrEP for HIV pre-
vention among MSM in Germany is cost-saving over 
a 40-year time period and leads to substantial health 
benefits in that it reduces the number of new HIV infec-
tions. Although PrEP is predicted to be cost-saving over 
a prolonged period of time, the overall HIV-related costs 
can increase in the first 10 years after introduction.
Our modelling results and cost-effectiveness analysis 
are in agreement with recent European modelling stud-
ies on the economic impact of PrEP in the Netherlands 
[9] and in the United Kingdom (UK) [24,25], countries 
that, similar to Germany, have an HIV epidemic concen-
trated among MSM. In the Netherlands, the introduc-
tion of generic versions of tenofovir and emtricitabine 
has reduced the price of PrEP by 90% [26]. At this price 
level and targeted to 10% of high-risk MSM, generic 
PrEP is predicted to be cost-saving in the Netherlands 
over a 40-year time period [9]. Similarly, Cambiano et 
al. report that PrEP targeted to high-risk MSM in the 
UK would be cost-saving within a 40-year time period 
and that a reduction of the cost of antiretroviral drugs 
(including drugs used as PrEP) would substantially 
shorten the time for cost savings to be realised [25]. 
Ong et al. found that PrEP targeted to high-risk MSM vis-
iting genito-urinary medicine clinics will be cost-saving 
over a 10-year time period if the price of generic PrEP 
is reduced as strongly as in Germany [24]. Contrary to 
our and others models [9,25], however, Ong et al. used 
a static model [24] which cannot assess the preven-
tive benefits of PrEP at population level and which may 
therefore underestimate the cost-effectiveness of PrEP.
The number of MSM at high risk of HIV infection who 
will use PrEP is a key parameter for the epidemiological 
and economic impact of a PrEP programme. Our mod-
elling study shows that if a larger proportion of indi-
viduals at high risk of infection are using PrEP, more 
HIV infections will be prevented and more costs will be 
saved in the long term. In the first decade after intro-
duction, however, a higher uptake of PrEP will result in 
higher economic expenses because in the short term, 
costs of PrEP will exceed the cumulative savings from 
averted HIV infections. Although the future uptake of 
PrEP in Germany is unknown, a web-based question-
naire found that 65% of participating HIV-negative 
MSM at risk of infection were willing to use PrEP [27].
Two independent randomised controlled trials showed 
that PrEP can prevent ca 85% of new infections if used 
daily [4] or if used on demand, where a high-risk indi-
vidual uses PrEP 2–24 h before sexual contact, fol-
lowed by additional dosages 24 h and 48 h after the 
last sexual contact [5]. Cost-effectiveness studies 
showed that on-demand PrEP is more cost-effective 
than daily use as such a dosing scheme uses fewer ten-
ofovir and emtricitabine tablets [9]. A PrEP demonstra-
tion project in the Netherlands, however, reported that 
almost three times more eligible MSM prefer the more 
expensive daily PrEP than on-demand PrEP [28]. In our 
analysis, we only included daily use of PrEP and found 
this approach to be cost-saving. In daily practice, some 
individuals will prefer an on-demand dosing scheme 
[28], which will reduce the costs of PrEP.
Our analyses predict that a reduction in the price of 
antiretroviral drug treatment will increase the time for 
cost savings to be realised. Importantly, the cost of 
antiretroviral drug treatment may strongly decrease 
as generic versions of TDF and emtricitabine cannot 
only be used as PrEP, but also in first-line treatment 
of HIV. We argue, however, that the costs of antiret-
roviral drug treatment in Germany will remain high. 
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Firstly, only one tenofovir prodrug, TDF, has become 
available as a generic product. The patent of another 
prodrug of tenofovir, TAF, will not expire in the com-
ing years. In Germany, TAF is preferred over TDF [18] as 
TAF is associated with a lower level of renal and bone 
mineral toxicity [29]. Indeed, a strong shift towards TAF 
based-regimens has been observed since 2016 across 
Germany [30]. Secondly, TDF and emtricitabine in HIV 
therapy have to be combined with a third drug. The 
most widely used third drug class are integrase strand 
transfer inhibitors such as dolutegravir or elvitegravir 
which are still protected by a patent [31] and will there-
fore remain costly in the coming years.
Our mathematical modelling analysis has several 
strengths. Firstly, we calibrated our model to the well-
described German HIV epidemic [11], which allowed 
us to make accurate epidemic predictions. Secondly, 
we used micro-costing to obtain the overall costs of 
HIV. Micro-costing, involving the detailed estimation 
of the unit costs of each component of resource use 
[19], is time-consuming and not frequently performed. 
Nonetheless, micro-costing is considered the most pre-
cise level of healthcare costing [19]. The final strength 
of our study is that we considered the population ben-
efit of PrEP using an HIV transmission model [9,25,32].
Our study has several limitations. Firstly, we did not 
consider risk compensation, defined as an increase 
in sexual risk behaviour in response to the use of 
PrEP, which can result in increased rates of bacterial 
sexually transmitted infections and hepatitis C virus 
infections. Although recent trials have not shown a 
substantial increase in risk behaviour [4], increases in 
bacterial sexually transmitted infections in those on 
PrEP in real-world settings [33]. In addition, infections 
with hepatitis C virus have been reported in a few HIV-
negative MSM that use PrEP [34]. Introduction of PrEP 
may therefore result in increased costs owing to higher 
rates of sexually transmitted infections. PrEP is, how-
ever, expected to remain cost-saving because bacterial 
sexually transmitted infections are treated with generic 
antibiotics that are cheap. Conversely, substantial 
increases in the incidence of hepatitis C, which require 
treatment with expensive direct-acting antiviral drugs 
[35], can result in a less favourable cost-effectiveness 
of PrEP. Secondly, previous modelling studies showed 
that PrEP is only cost-effective when targeted to indi-
viduals at a high risk of HIV infection [36]. It cannot 
be ruled out that MSM who are at low risk of infection 
perceive themselves to be at high risk and therefore 
start using PrEP. Our sensitivity analysis, however, pre-
dicted that introduction of PrEP remains cost-saving 
even when a substantial proportion of MSM at low risk 
of infection start using PrEP. Thirdly, we assumed that 
the German HIV epidemic among MSM will remain at 
a similar level as it is today if PrEP is not introduced. 
The number of new HIV diagnoses among MSM in the 
Netherlands [10] and the UK [37] has declined in recent 
years, which has been ascribed to increased test-
ing followed by immediate treatment in those testing 
positive. A similar decline in Germany would decrease 
the costs that can be saved and prolong the time for 
cost-savings to be realised.
Conclusion
Introduction of PrEP in Germany can reduce the HIV 
epidemic among MSM in a cost-saving manner. PrEP 
is predicted to remain cost-saving even when generic 
versions of antiretroviral drug treatment become avail-
able. Introduction of PrEP will, however, require short-
term financial investments which are predicted to 
result in substantial cost-savings after a period of at 
least 10 years.
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